Table 3.
HR and 95% CI on 1st, 2nd, 3rd, 4th, 5th, 6th, 7th, 8th, 9th, 10th, 11th, and 12th month PFS for immunotherapy combinations compared to placebo.
| Time (months) | Serp | Atez | Durv | Adeb | Nivo | Atez-Tira | Durv-Trem | Pemb | Ipi | Pla |
|---|---|---|---|---|---|---|---|---|---|---|
| 1st | 1.99 (0.12,31.98) | 1.99 (0.18,22.10) | – | 1.99(0.18,22.10) | 2.08 (0.50,8.63) | 1.77 (0.51,6.14) | – | – | – | Reference |
| 2nd | 2.21 (0.02,239.30) | – | 1.27 (0.01,134.76) | – | 1.22 (0.01,146.78) | 1.61 (0.01,177.60) | 1.14 (0.01,120.44) | – | – | Reference |
| 3rd | 1.96 (0.39,9.89) | 1.03 (0.21,5.10) | 1.18 (0.12,11.27) | – | 2.61 (0.44,15.56) | 1.21 (0.24,6.11) | 1.06 (0.22,5.09) | – | – | Reference |
| 4th | 2.09 (0.28,15.58) | 1.08 (0.14,8.05) | 1.15 (0.16,8.48) | 1.13 (0.15,8.53) | 1.50 (0.19,12.07) | 1.27 (0.17,9.55) | – | 1.04 (0.14,7.72) | – | Reference |
| 5th | 2.67 (1.27,5.62) | 1.54 (0.72,3.30) | – | 1.29 (0.60,2.76) | 1.57 (0.64,3.89) | – | – | 1.35 (0.64,2.87) | 1.00 (0.50,1.99) | Reference |
| 6th | 3.31 (2.25,4.87) | 1.56 (1.00,2.43) | – | 1.61 (1.11,2.33) | 1.74 (0.90,3.36) | – | – | 1.69 (1.12,2.55) | 1.32 (1.00,1.74) | Reference |
| 7th | 3.77 (2.52,5.63) | 1.81 (1.10,2.96) | 1.14 (0.78,1.67) | 1.81 (1.10,2.96) | 2.40 (1.15,5.03) | – | 1.08 (0.74,1.59) | 1.81 (1.10,2.96) | 1.19 (0.88,1.60) | Reference |
| 8th | 3.92 (2.54,6.05) | 1.98 (1.16,3.39) | 1.61 (1.08,2.41) | 2.26 (1.47,3.46) | 3.00 (1.23,7.30) | – | 1.34 (0.89,2.02) | 2.48 (1.48,4.16) | 1.31 (0.95,1.82) | Reference |
| 9th | 3.56 (2.26,5.61) | 1.58 (0.90,2.80) | 1.63 (1.04,2.55) | 2.68 (1.63,4.41) | 3.03 (1.19,7.72) | – | 1.59 (1.02,2.49) | 2.52 (1.38,4.61) | 1.59 (1.09,2.32) | Reference |
| 10th | 3.51 (2.20,5.62) | 1.98 (1.06,3.72) | 1.78 (1.11,2.87) | 3.42 (1.91,6.15) | 5.13 (1.64,16.02) | – | 1.66 (1.02,2.68) | 2.71 (1.44,5.10) | 1.80 (1.20,2.71) | Reference |
| 11th | 4.02 (2.42,6.69) | 2.10 (1.09,4.05) | 2.64 (1.54,4.55) | 3.34 (1.85,6.00) | 4.03 (1.26,12.84) | – | 2.51 (1.46,4.33) | 3.34 (1.85,6.00) | 1.47 (0.96,2.23) | Reference |
| 12th | 3.21 (1.92,5.37) | 2.47 (1.18,5.16) | 3.97 (2.13,7.40) | 3.89 (2.07,7.31) | 2.65 (0.89,7.90) | – | 3.68 (1.97,6.87) | 4.90(2.11,11.38) | 1.42 (0.88,2.28) | Reference |
Nivo, nivolumab; Atez-Tira, tiragolumab; Atez, atezolizumab; Serp, serplulimab; Durv, Durvalumab; Durv-Trem, Durvalumab + tremelimumab; Pla, Placebo; Adeb, Adebrelimab; Pemb, Pembrolizumab; Ipi, ipilimumab.Significant results were in bold.